Novel oral anticoagulants (OAC) are being increasingly used. We describe a case of increased bleeding tendency resulting from probable drug interaction between rivaroxaban and topical miconazole. Recognition of this possible interaction is important during concomitant use to prevent adverse outcome arising from over-anticoagulation.
ZhangWRamamoorthyYKilicarslanTNolteHTyndaleRFSellersEM. Inhibition of cytochromes p450 by antifungal imidazole derivatives. Drug Metab Dispos2002;30(3):314–8.
2.
MueckWKubitzaDBeckaM. Co-administration of rivaroxaban with drugs that share its elimination pathways: Pharmacokinetic effects in healthy subjects. Brit J Clin Pharmaco2013;76(3):455–66 doi: 10.1111/bcp.12075.
3.
DevarajAO'BeirneJ PVeaseyRDunkA. Interaction between warfarin and topical miconazole cream. BMJ2002;325(7355):77 doi: 10.1136/bmj.325.7355.77.
4.
BroosNEugenePPuijenbroekV. Interaction between topical miconazole and coumarins. Eur J Clin Pharmacol2010;66(11):1171–2 doi: 10.1007/s00228-010-0874-6.
5.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEA. A method for estimating the probability of adverse drug reactions. Clin Pharm Ther1981:30(2):239–45 doi: 10.1038/clpt.1981.154.
6.
BaglinTKeelingDKitchenS. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the british committee for standards in haematology. Brit J Haematol2012;159(4):427–9 doi: 10.1111/bjh.12052.
7.
SamamaMMContantGSpiroTEPerzbornELe FlemLGuinetC. Laboratory assessment of rivaroxaban: A review. Thrombosis J2013; 11(1):11 doi: 10.1186/1477-9560-11-11.
